Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ISTA: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

ISTA Pharmaceuticals Reports Second Quarter 2009 Financial Results and Raises Full Year Revenue Guidance ISTA

62%

-14.29% in 94 days <font> <font>   Wednesday, August 05, 2009 4:00:00 PM ET </font> <> ISTA Pharmaceuticals, Inc. ( ISTA ), today reported financial results for the three months ended June 30, 2009. ISTA reported net revenue of $24.0 million for the three months ended June 30, 2009, a 35% increase over the same period of 2008. ISTA’s operating loss for the second quarter ended June 30, 2009 was $1.6 million or a 79% reduction from $7.8 million for the same period in 2008. As a result of the strong quarter, ISTA raised its guidance range for full year 2009 revenue to between $95 and $100 million. IS<><><>< />< />< />< />< />< />< />< />< />< />< />< />< />< />< /><><><><><><><><><>< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< /><><><><><><><><><><>< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< /><><><><>< />... Continue reading »

Target Price Raised ISTA

N/A

-5.05% in 132 days   06/29/09 - RBC Capital Markets <> <> NEW YORK, June 29 (newratings.com) - Analysts at RBC Capital Markets maintain their "sector perform" rating on ISTA Pharmaceuticals (ISTA) . The target price has been raised from $3 to $5. In a research note published this morning, the analysts mention that an FDA panel has voted 7-0 in favour of approving Bepreve. The FDA approval reduces some risk related to the approval of Bepreve, the analysts say. ISTA Pharmaceuticals is likely to launch the drug by in January 2010, RBC Capital Markets adds. The company’s share price has, ho... Continue reading »

Target Price Raised ISTA

N/A

-5.05% in 132 days   06/29/09 - RBC Capital Markets <> <> NEW YORK, June 29 (newratings.com) - Analysts at RBC Capital Markets maintain their "sector perform" rating on ISTA Pharmaceuticals (ISTA) . The target price has been raised from $3 to $5. In a research note published this morning, the analysts mention that an FDA panel has voted 7-0 in favour of approving Bepreve. The FDA approval reduces some risk related to the approval of Bepreve, the analysts say. ISTA Pharmaceuticals is likely to launch the drug by in January 2010, RBC Capital Markets adds. The company’s share price has, ho... Continue reading »

FDA Extreme Trades: 16 Stocks Under $5 ISTA

73%

-7.89% in 134 days <> Below are FDA extreme trades among 16 companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> (database includes 225 entries as of 6/27/09) which have pending FDA decisions for either new drug products, biological agents, medical devices, or diagnostic tests that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <> <font> Extreme FDA and Clinical Trial Calendar Trade... Continue reading »

Bullish on ISTA ... ISTA

N/A

+92.86% in 182 days ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye in the United States. The company offers Xibrom for the treatment of inflammation and pain following cataract surgery; Istalol for the treatment of glaucoma; and Vitrase for use as a spreading agent. Its developing products include Bepotastine ophthalmic solution for allergic conjunctivitis; T-Pred, a Phase III clinical trial product candidate for the treatment of steroid-responsive inflammatory ocular conditions; Ecabet S... Continue reading »

From the Blogosphere

Trading FDA Decisions: 14 Extreme Trades

73%

Below is a summary of companies from the BioMedReports.com FDA Decision Date Calendar which have market caps below $200M, making them ideal candidates for extreme stock price volatility trades as their decision dates become imminent. Dyax Corp. (DYAX) secured a narrow approval from a FDA Advisory Panel in early February (with a 6-5-2 vote) for its Kalbitor (ecallantide or DX-88) BLA with a PDUFA date of 3/23/09, which is designated for priority review in the treatment of acute attacks of hereditary angioedema (HAE is a rare disorder marked by severe swelling which can be fatal if the throat ... Continue reading »

FDA Decision Calendar: 16 Extreme Trades

73%

Click here for a link to my previous FDA calendars and the list below highlights 16 companies with pending new product decisions at the agency + market caps below $150M, making them ideal candidates for extreme stock price volatility trades. BioDelivery Sciences (BDSI) – Onsolis approval is possible by mid-2009 and the Company raised $6M in cash from partner Meda AB, representing a $3M expanded licensing agreement + a $3M advance of the $30M milestone payment upon FDA approval. The remaining $27M cash milestone payment on FDA approval for Onsolis represents nearly one-half of the Company's< />< /><>< />< />< />< /><>< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< /><><>< /><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< />< />... Continue reading »

FDA Decision Calendar: Extreme Trades

73%

<>The accompanying table [click to enlarge] includes an updated calendar of 78 expected FDA new product decisions with more detailed comments for each entry. Click here for a link to my previous FDA calendars and the list below highlights companies with pending decisions + market caps below $100M, making them ideal candidates for extreme trading opportunities. BioDelivery Sciences (BDSI) – Onsolis approval is possible by mid-2009 and the Company recently raised $6M in cash from partner Meda AB, representing a $3M expanded licensing agreement + a $3M advance of the $30M milestone payment upon< />< />< />< /><>< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< />< /><><>< /><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< />< />... Continue reading »

Updated FDA Calendar of 73 Decision Dates

73%

The accompanying table [click to enlarge or download] includes an updated calendar of 75 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, which includes a full slate of expected action before year-end outlined in my previous article. The last few days have been busy for antibiotics at the agency, resulting in sharply lower stock prices for Targanta Therapeutics (TARG) and Theravance (THRX). An FDA panel voted against Targanta's oritavancin, which has an upcoming decision in early December and sent shares crashing from 8 bucks before the dec... Continue reading »

Updated FDA Calendar of 73 Decision Dates

73%

The accompanying table [click to enlarge or download] includes an updated calendar of 75 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, which includes a full slate of expected action before year-end outlined in my previous article. The last few days have been busy for antibiotics at the agency, resulting in sharply lower stock prices for Targanta Therapeutics (TARG) and Theravance (THRX). An FDA panel voted against Targanta's oritavancin, which has an upcoming decision in early December and sent shares crashing from 8 bucks before the dec... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.